ClinicalTrials.gg
RecruitingNCT06772701EPDS-PEREUpdated Jan 21, 2026

Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father

An interventional study of Mini International Neuropsychiatric Interview and EPDS book in Depression, Postpartum, sponsored by Groupe Hospitalier du Havre. Recruiting at 2 sites in France. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Groupe Hospitalier du Havre · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2024, registered Jan 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Depression, Postpartum with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Depression, Postpartum · France.

Planned enrollment
4th of 12
1,000 · median 364
Started
2024
with 3 others
No phase
11 of 24
3 open now
Registered
21st of 24
by date

Among the 24 studies in Depression, Postpartum with a site in France, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 21st registered.

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

6 of the 24 studies in Depression, Postpartum with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Depression, Postpartum with a site in France, or all of them as a file.
02

Study summary

In recent years, fatherhood has changed considerably. Fathers are now more involved during the perinatal period, with their partner but also in caring for the child. Investigators now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. These upheavals can lead to depression that must be detected and treated as early as possible. This is an easy screening to perform using the EPDS (Edinburgh Postnatal Depression Scale). Currently, the EPDS is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. Indeed, it is systematically recommended in many countries. It is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period.

The main objective is to validate the use of the EPDS scale as a screening tool for postnatal depression in a population of French fathers.

They complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

Read the detailed description

Fathers complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

03

Conditions studied

  • Depression, Postpartum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All fathers whose baby is 10 days old or less

Exclusion criteria

Exclusion Criteria:

  • People with a poor understanding of spoken or written French
  • Minors
  • Persons under court protection, guardianship or curatorship
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Fathers included at the maternity hospital or through their wife

    At inclusion, fathers included at the maternity hospital or through their wife take the Mini International Neuropsychiatric Interview and complete the EPDS book (PH-Q9, EPDS and socio-demographic questionnaire). 6 to 8 weeks after the birth of their child, they complete only EPDS book.

    Diagnostic Test: Mini International Neuropsychiatric Interview · Other: EPDS book

  • Experimental
    fathers includes through the awareness campaign

    At inclusion, fathers included through the awareness campaign have only the EPDS book (PH-Q9, EPDS and socio-demographic questionnaire) at inclusion. 6 to 8 weeks after the birth of their child, they complete the same EPDS book.

    Other: EPDS book

Interventions

  • Diagnostic testMini International Neuropsychiatric Interview

    Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression

  • OtherEPDS book

    PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.

06

What researchers measure

Primary outcomes

  1. Mini International Neuropsychiatric Interview

    This short structured clinical interview is used to diagnose psychiatric disorders and is currently the gold standard for diagnosing depression.

    Time frame: at inclusion

Secondary outcomes

  1. socio-demographic questionnaire

    Socio-demographic data will be a secondary evaluation criterion. It will be used to study risk and protective factors, both those already known in the literature and those that have been little studied, and to identify profiles that are more at risk, with a view to taking preventive action in the field.

    Time frame: at inclusion and 6 to 8 weeks after the birth of their child

07

Study locations

2 of 2 sites recruiting
  • Antoine-Béclère hospital AP-HP
    Clamart, 92140, France
    Enrolling by invitation
  • Le Havre hospital - site Jacques Monod
    Montivilliers, 76290, France
    Recruiting
    • PICARD Angélique · Contact0232734856
    • Gisèle APTER, Professor - child psychiatry · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 30 months after the start.

Of 259 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 30 months is above that.

Counting every sponsor, half of 265 studies reached it within 23 months; a quarter within 11 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 13, 2025
StartActual
Jul 11, 2024
Primary completionEst.
Jan 12, 2027
CompletionEst.
Mar 12, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06772701
Lead sponsor
Groupe Hospitalier du Havre
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jul 11, 2024
Primary completion
Jan 12, 2027 (estimated)
Completion
Mar 12, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Angélique PICARD, project coordinator
Contact
angelique.picard@ch-havre.fr
+33232734856
Christophe FRUIT, CRA
Contact
cellule.rechercheclinique@ch-havre.fr
+33232734857

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion